ANVS logo.jpg
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
October 02, 2024 08:30 ET | Annovis Bio, Inc.
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands...
NodThera_logo.jpg
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
August 05, 2024 10:16 ET | NodThera
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...
NodThera_logo.jpg
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
August 01, 2024 07:00 ET | NodThera
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 -...
Changes in MMSE after treatment with 10mg or 20mg buntanetap compared to baseline and placebo Figure 1
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
July 02, 2024 08:00 ET | Annovis Bio, Inc.
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson’s patients with substantial cognitive decline exhibited a...
Vaccinex logo
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024 08:30 ET | Vaccinex, Inc.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
fundamental pharma.png
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
March 20, 2024 02:00 ET | Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative...
Astrocyte Logo.png
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
March 12, 2024 12:00 ET | Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
fundamental pharma.png
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
February 07, 2024 08:00 ET | Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
Kizoo_Logo for GNW (2).jpg
Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain
January 18, 2024 08:00 ET | KIZOO Technology Capital GmbH
SAN FRANCISCO and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related...